相似文献
1
Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR.
J Clin Microbiol. 2003 Aug;41(8):3897-900. doi: 10.1128/JCM.41.8.3897-3900.2003.
2
Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay.
Antiviral Res. 2004 Jun;62(3):121-3. doi: 10.1016/j.antiviral.2003.12.005.
3
Antiviral drug susceptibility of human herpesvirus 8.
Antimicrob Agents Chemother. 1997 Dec;41(12):2754-6. doi: 10.1128/AAC.41.12.2754.
4
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
AIDS. 1997 Sep;11(11):1327-32. doi: 10.1097/00002030-199711000-00006.
5
In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.
Am J Vet Res. 2004 Apr;65(4):399-403. doi: 10.2460/ajvr.2004.65.399.
6
Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry.
Antiviral Res. 2003 Apr;58(2):149-57. doi: 10.1016/s0166-3542(02)00210-3.
7
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Nihon Rinsho. 1998 Jan;56(1):140-4.
8
Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis.
Cytometry. 2000 Jun 1;40(2):135-40. doi: 10.1002/(sici)1097-0320(20000601)40:2<135::aid-cyto7>3.0.co;2-h.
9
Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.
Antiviral Res. 2003 Apr;58(2):159-65. doi: 10.1016/s0166-3542(02)00211-5.
10
In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet.
Vet Microbiol. 2007 May 16;122(1-2):43-51. doi: 10.1016/j.vetmic.2007.01.004. Epub 2007 Jan 14.
引用本文的文献
1
Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.
Viruses. 2021 Sep 9;13(9):1797. doi: 10.3390/v13091797.
2
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir.
AIDS Res Ther. 2019 Jul 27;16(1):15. doi: 10.1186/s12981-019-0230-6.
3
Inhibition of Tip60 Reduces Lytic and Latent Gene Expression of Kaposi's Sarcoma-Associated Herpes Virus (KSHV) and Proliferation of KSHV-Infected Tumor Cells.
Front Microbiol. 2018 Apr 24;9:788. doi: 10.3389/fmicb.2018.00788. eCollection 2018.
4
Role of Pattern Recognition Receptors in KSHV Infection.
Cancers (Basel). 2018 Mar 20;10(3):85. doi: 10.3390/cancers10030085.
5
Viral Oncology: Molecular Biology and Pathogenesis.
J Clin Med. 2017 Nov 29;6(12):111. doi: 10.3390/jcm6120111.
6
Kaposi sarcoma herpesvirus pathogenesis.
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732). doi: 10.1098/rstb.2016.0275.
7
KSHV targeted therapy: an update on inhibitors of viral lytic replication.
Viruses. 2014 Nov 24;6(11):4731-59. doi: 10.3390/v6114731.
8
Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.
Antimicrob Agents Chemother. 2014 Dec;58(12):7312-23. doi: 10.1128/AAC.03957-14. Epub 2014 Sep 29.
9
Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays".
J Clin Microbiol. 2013 Jun;51(6):2014. doi: 10.1128/JCM.00545-13.
10
Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.
J Clin Microbiol. 2013 Jun;51(6):2013. doi: 10.1128/JCM.00504-13.
本文引用的文献
1
Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease.
J Med Virol. 2002 Nov;68(3):399-403. doi: 10.1002/jmv.10217.
2
Application of real-time PCR for determination of antiviral drug susceptibility of herpes simplex virus.
Antimicrob Agents Chemother. 2002 Sep;46(9):2943-7. doi: 10.1128/AAC.46.9.2943-2947.2002.
3
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
N Engl J Med. 2002 Apr 11;346(15):1119-26. doi: 10.1056/NEJMoa011759.
4
Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
J Infect Dis. 2001 Dec 15;184(12):1598-602. doi: 10.1086/324672. Epub 2001 Dec 3.
5
Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma.
J Infect Dis. 2000 Jun;181(6):1940-9. doi: 10.1086/315503. Epub 2000 May 26.
6
Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Clin Pharmacokinet. 1999 Aug;37(2):167-76. doi: 10.2165/00003088-199937020-00005.
7
Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
N Engl J Med. 1999 Apr 8;340(14):1063-70. doi: 10.1056/NEJM199904083401402.
8
Antiviral drug susceptibility of human herpesvirus 8.
Antimicrob Agents Chemother. 1997 Dec;41(12):2754-6. doi: 10.1128/AAC.41.12.2754.
9
Effect of DNA synthesis inhibitors on Kaposi's sarcoma-associated herpesvirus cyclin and major capsid protein gene expression.
AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1229-33. doi: 10.1089/aid.1997.13.1229.
10
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
AIDS. 1997 Sep;11(11):1327-32. doi: 10.1097/00002030-199711000-00006.
Zotero 插件